Interim report of the safety and immunogenicity endpoints from the Phase II/III study has been submitted to the Drug Controller General of India (DCGI) f...
The purpose of this trial is to assess the safety, tolerability, and efficacy of multiple ascending doses of ALZN002 compared with that of placebo in 20-30...
Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer’s disease (AD) Modulation of neuroinflammati...
Søren Tulstrup, President and CEO, Hansa Biopharma said, "This phase 2 study of imlifidase in GBS is an important next step in understanding the rol...
© 2024 Biopharma Boardroom. All Rights Reserved.
